Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ridinilazole - Summit Therapeutics

Drug Profile

Ridinilazole - Summit Therapeutics

Alternative Names: SMT-19969

Latest Information Update: 20 Jun 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Summit plc
  • Developer Summit Therapeutics
  • Class Antibacterials; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium difficile infections

Most Recent Events

  • 18 Jun 2019 Biomedical Advanced Research and Development Authority (BARDA) increases the value of its award in Clostridium difficile infections
  • 13 Feb 2019 Phase-III clinical trials in Clostridium difficile infections in USA, Canada, Europe, Asia, Australia and Latin America (PO)
  • 03 Oct 2018 Antimicrobial data from a phase II trial in Clostridium difficile infections presented at the at IDWeek (IDW-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top